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Summary
The antiestrogen tamoxifen is extensively metabolized in patients to form a series of compounds with altered
affinity for estrogen receptors (ERs), the primary target of this drug. Furthermore, these metabolites exhibit a
range of partial agonist and antagonist activities for ER mediated effects that do not depend directly on their
absolute affinity for ERs. Thus, clinical response to tamoxifen therapy is likely to depend on the aggregate effect
of these different metabolites resulting from their abundance in the patient, their affinity for the receptors, and
their agonist/antagonist profile. A recent study has shown that plasma concentrations of the tamoxifen metabolite
4-hydroxy-N-desmethyl tamoxifen (endoxifen), in patents undergoing tamoxifen therapy, are dependent on the
cytochrome P450 (CYP) 206 genotype of the patient and that medications commonly prescribed to patients on
tamoxifen therapy can also inhibit endoxifen production. In this study we characterized the properties of this
metabolite with respect to binding to ERs, ability to inhibit estrogen stimulated breast cancer cell proliferation and
the regulation of estrogen responsive genes. We demonstrate that endoxifen has essentially equivalent activity to
the potent metabolite 4-hydroxy tamoxifen (4-OH-tam) often described as the active metabolite of this drug. Since
plasma levels of endoxifen in patients with functional CYP2D6 frequently exceed the levels of 4-OH-tam, it seems
likely that endoxifen is at least as important as 4-OH-tam to the overall activity of this drug and suggests that
CYP2D6 status and concomitant administration of drugs that inhibit CYP2D6 activity have the potential to affect
response to tamoxifen therapy.
Introduction
It is estimated that in 2002 there were 203,500 women
newly diagnosed with breast cancer and that 39,600
woman died of the disease [1]. Roughly 60–65%
of these women will have tumors that are estrogen
receptor (ER) positive. Of ER positive tumors, ap-
proximately 60–65% will respond to some form of
hormonal therapy. Since its introduction 30 years ago,
tamoxifen has been the front line hormonal therapy of
choice [2]. With the additional use of tamoxifen in the
adjuvant setting, and now with evidence that it is an ef-
fective chemo-preventive agent, it is not surprising that
tamoxifen is the most commonly prescribed drug in
the management of breast cancer. Tamoxifen is a se-
lective estrogen receptor modulator (SERM) – that is
a compound which competes with estrogen for bind-
ing to the ER and exhibits a spectrum of estrogen
antagonist and agonist activity depending on the site
of action. In the breast it is primarily an antiestrogen
and it is believed to inhibit tumor growth by starving
the tumor cells of survival and proliferative signals
provided by estrogen signaling.
Tamoxifen is sometimes described as a pro-drug,
since it is extensively metabolized yielding several
compounds that are more potent antiestrogens than
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the parent compound [3]. However, tamoxifen is quite
active itself and due to the relatively low concentra-
tion of the more potent metabolites, it seems likely
that the overall response of the tumor is the result
of the aggregate effect of the drug and its metabo-
lites. Interestingly, some minor tamoxifen metabolites
are potent estrogens and many investigators have sug-
gested that different patterns of metabolism of the
compound among patients might go some way to ex-
plaining why only approximately 60% of ER positive
tumors respond to tamoxifen therapy.
We recently reported the identification of a tamox-
ifen metabolite (4-hydroxy-N-desmethyl tamoxifen –
endoxifen), the plasma concentration of which in
patients receiving tamoxifen is altered by concomi-
tant administration of paroxetine [4]. Furthermore, we
showed that plasma concentrations were dependent
on the genotype of the patient with respect to poly-
morphisms of an enzyme known to metabolize both
paroxetine and tamoxifen (cytochrome P450 2D6 –
CYP2D6) [5]. In this study we present a detailed
characterization of the ER binding properties of this
metabolite and its effects on the expression of estro-
gen responsive genes and on the proliferation of ER
positive breast cancer cells.
Methods
All chemicals were from Sigma (St. Louis, MO)
unless otherwise noted.
Synthesis and purification of endoxifen
Endoxifen for use in this study was synthesized using
two separate methods. The first method is described
in our previous paper [4]. The second method was
developed to facilitate the synthesis of large amounts
of the compound for in vitro and in vivo character-
ization and is summarized in Figure 1. The product
of each reaction was purified using silica gel chro-
matography. Endoxifen was purified following the
final reaction using silica gel chromatography with
90:9:1 CHCl3/CH3OH/NH4OH as the eluent. Using
1H NMR, 13C NMR and high resolution mass spectro-
metry, the identity of the final product was confirmed
as a 1:1 mixture of E and Z regioisomers of endoxifen
(spectra are available upon request). Endoxifen pre-
pared by either method produced identical results in
the assays described below.
Figure 1. Synthetic scheme for the production of endoxifen. (a)
KH, bromoethane, THF, DMF, reflux, 17% yield; (b) propiophen-
one, TiCl4, Zn dust, THF, reflux, 65% yield; (c) CH3NH2 in MeOH,
85◦, 70–90% yield.
Cell culture
MCF-7, T47D and BT474 cells were obtained from
the tissue culture shared resource (TCSR) at the
Lombardi Comprehensive Cancer Center and were
routinely cultured in modified IMEM supplemented
with 10% fetal calf serum (Life Sciences, Gaithers-
burg, MD).
Proliferation assays. Cell monolayers at about 70%
confluence were withdrawn from estrogen by chan-
ging to an estrogen-depleted medium consisting of
phenol red-free modified IMEM supplemented with
charcoal stripped newborn calf serum. To remove re-
sidual estrogen the monolayer was washed every hour
for 5 h with phenol red-free IMEM and cultured in
fresh medium in between washes. The cells were then
cultured overnight and trypsinized with phenol red-
free trypsin. The cells were counted and 1000 cells
plated into each well of several 96 well plates in 100 µl
of the same medium. After allowing the cells to at-
tach (5 h), 100 µl of medium containing 17-β-estradiol
(E2), endoxifen, or 4-OH-tam (alone or in combi-
nation with E2), or the vehicle control (ethanol), were
added to the wells to yield the indicated concentrations
of the various compounds and a final ethanol concen-
tration of 0.1%. Several duplicate plates were prepared
and after allowing the cells to grow for various peri-
ods, the cells were stained with crystal violet (0.52%
crystal violet in 25% methanol). After washing the
plates to remove excess stain, the plates were dried and
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then the bound stain solubilized by addition of 100µl
of 100 mM sodium citrate in 50% ethanol. Staining
intensity, which is proportional to cell number, was
then determined by measuring absorbance at 570 nm
using a 96 well plate reader [6].
ER binding assays
The binding of endoxifen to the ERs was investig-
ated by competition binding assays using two different
methods. The dextran coated charcoal method and a
fluorescence polarization method were used to evalu-
ate binding to ER-α, and the fluorescence polarization
method was used to investigate binding to ER-β.
Dextran coated charcoal assay. Competitive binding
assays were conducted using a modification of a stan-
dard method [7]. Briefly, MCF-7 cells were withdrawn
from estrogen by washing and growth in depleted me-
dium (as described above) for 3 days to maximize
ER levels. The cells were harvested with phenol red-
free trypsin (Biofluids, Rockville, MD) washed with
TEG buffer (10 mM Tris, pH 7.4, 1 mM EDTA, 10%
glycerol) and re-suspended at approximately 30 mil-
lion cells per ml in TEG buffer supplemented with
1 mM dithiothreitol, 0.5 M NaCl and protease inhib-
itors (1 mg/ml leupeptin, 77 µg/ml aprotinin, 1 µg/ml
pepstatin A and 250 µg/ml pefabloc). A whole cell
lysate was prepared by homogenization with a tef-
lon/glass homogenizer (40 strokes on ice) followed
by centrifugation at 105,000× g for 30 min at 4◦C.
The supernatant was removed and the protein concen-
tration measured using the method of Bradford [8].
The protein concentration in the lysate was adjusted
to 2 mg/ml by dilution with the lysis buffer.
Binding reactions were set up on ice in disposable
glass culture tubes (Fisher, Pittsburgh, PA). Whole cell
lysate (100 µl) was mixed with 50 µl of TEG buf-
fer containing drugs to yield a final concentration of
1 nM 3H E2 (TRK 322, Amersham, Piscataway, NJ)
in the absence or presence of various concentrations
of unlabeled E2, endoxifen or 4-hydroxy tamoxifen
(4-OH-tam). After an overnight incubation at 4◦C the
unbound steroids were removed by the addition of
500 µl of a 0.5% suspension of activated charcoal in a
0.05% solution of dextran (70,000 average molecular
weight), 10 mM Tris, pH 8. The charcoal was pelleted
by centrifugation and 500 µl of the supernatants from
each tube was placed in scintillation vials with 5 ml
of Ecoscint A (National Diagnostics, Atlanta GA) and
relative levels of binding determined by scintillation
counting.
Fluorescence polarization assay. Fluorescent polari-
zation based competition binding assays were con-
ducted to determine the relative affinity of 4-OH-tam
and endoxifen for ER-α and ER-β using commercially
available kits (P2698 and P2700 respectively, PanVera
Corp., Madison, WI). Assays were conducted us-
ing a modification of the manufacturer’s instructions.
Briefly, serial dilutions of E2, endoxifen or 4-OH-tam
were prepared in ES2 screening buffer (100 mM po-
tassium phosphate, pH7.4, 100 µg/ml bovine gamma
globulin) and 10 µl of each concentration was ali-
quoted into four wells of a black 384 well assay
plate (3676 Corning, Corning, NY). Ten microliters
of a solution containing 20 nM recombinant ER (α or
β), and 2 nM of a proprietary fluorescent ER ligand
(FluormoneTM) was added to each well. The plate
was shaken on a plate mixer and incubated for 5 h in
the dark at room temperature. Fluorescence polariza-
tion signals were then measured using a Tecan Ultra
fluorometer (Tecan, Durham, NC).
RNA preparation and analysis
MCF-7 cells were depleted of estrogen for 24 h as
described above and then plated into 25 cm2 flasks
(Costar, Corning, NY). The medium was replaced
every 24 h (phenol red free IMEM with 10% CCS)
for 5 days after which the cells were treated with the
indicated concentration of endoxifen or 4-OH-tam in
the presence or absence of estradiol for 2 or 3 days.
The monolayers were washed twice with phosphate
buffered saline (PBS) and then solublized in RNAzol
(Iso-Tex Diagnostics, Friendswood, TX), and total
cellular RNA prepared according to the manufacturers
instructions.
Northern blot analysis. Northern blot hybridization
was conducted essentially as described previously [9].
Briefly 5 µg samples of RNA were fractionated on
1.2% agarose gels containing 2.2 M formaldehyde
and transferred to nylon membranes (Hybond-N,
Amersham, Arlington Hights, IL). The uniformity of
RNA transfer was verified by examining the ethidium-
stained ribosomal RNA bands on the filters under
UV illumination. The filters were then hybridized us-
ing conditions previously described with riboprobes
transcribed from plasmids containing cDNAs for the
various genes being studied [9]. After washing, the
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Figure 2. Relative ER binding affinity of endoxifen. The ability of various concentrations of endoxifen, 4-OH-tam and estradiol to displace 3H
estradiol (A) or a synthetic fluorescent estrogen (B and C) from MCF-7 nuclear extracts (A) or recombinant preparations of the α (B) or β (C)
form of the ER were evaluated as described in Methods. The mean and standard deviation of at least 2 (A) or 4 (B and C) independent samples
are presented for each point.
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radioactive bands on the filters were imaged and
quantitated with a phosphorimager (Molecular Dy-
namics model 445 SI, Sunnyvale, CA). Probes for
pS2 and 36B4 were provided by Pierre Chambon
(INSERM, Strasbourg, France) and a probe for
Cathepsin D was provided by Dr Bruce Westley (Uni-
versity of Newcastle upon Tyne, UK).
Results
ER binding assays
To evaluate the ability of endoxifen to bind to the ER,
classic radioligand receptor competition binding as-
says were conducted using cell extracts from ER pos-
itive breast cancer cells, as described in the methods
section [7]. Figure 2(A) shows data from a represen-
tative experiment using MCF-7 cells. Each data point
is the mean and standard deviation of two or three
samples and each experiment was conducted at least
twice. From these data the apparent relative affinity
of 4-OH-tam and endoxifen was calculated to be ap-
proximately 35 and 25% that of estradiol, respectively
under the experimental conditions used.
To further probe the ER binding characteristics of
endoxifen, fluorescence polarization based receptor
binding assays were conducted using recombinant hu-
man estrogen receptor alpha (ER-α). Comparison of
the ability of 4-OH-tam and endoxifen to displace a
proprietary fluorescent estrogen from the recombinant
ER-α demonstrated that the compounds have an es-
sentially identical affinity for the receptor under these
conditions (Figure 2(B)). Similar experiments were
conducted to evaluate binding to the beta form of the
receptor (ER-β), which showed that both compounds
had apparently identical affinity for this receptor also
(Figure 2(C)).
Proliferation assays
Assays were conducted to characterize the ER ag-
onist and antagonist properties of endoxifen with re-
spect to the proliferation of several ER positive breast
cancer cell lines (MCF-7, T47D and BT474). The
proliferation of these cell lines is dependent on es-
trogenic stimuli and initial studies were conducted to
determine the minimum concentration of estradiol re-
quired to maximally stimulate the growth of the cells
(Figure 3(A)). The dose–response relationship exhib-
ited by all three lines was very similar, with maximal
proliferation being produced by stimulation with ap-
proximately 200 pM estradiol which was chosen as
the dose for subsequent experiments (dotted line in
Figure 3. Inhibition of estradiol stimulated breast cancer cell pro-
liferation by endoxifen and 4-OH-tam. MCF-7, T47D and BT474
cells were withdrawn from estrogen stimulation and treated with
the indicated concentration of estradiol for 7–9 days (A). The abil-
ity of endoxifen or 4-OH-tam to inhibit the proliferation stimulated
by 200 pM estradiol (B) or stimulate cell proliferation in the ab-
sence of estrogen (C) was then tested by growing the cells for
7–9 days in the indicated concentration of endoxifen or 4-OH-tam
200 pM of estradiol in the presence (B) or absence (C) of 200 pM
estradiol.
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Figure 3. Continued.
Figure 4. Inhibition of estrogen induced pS2 expression by endox-
ifen or 4-OH-tam. Cells were withdrawn from estradiol and treated
with 200 pM estradiol in the presence of the indicated concentration
of endoxifen or 4-OH-tam for 3 days. pS2 mRNA levels were de-
termined as described in Methods and are expressed as a percentage
of maximal pS2 levels normalized to total RNA. The experiment
was repeated three times – representative data are presented.
Figure 3(A)). The ability of 4-OH-tam and endoxifen
to inhibit the estrogen stimulated growth of the breast
cancer cells was examined and both compounds were
found to be essentially equipotent, with half max-
imal inhibition being seen at approximately 50 nM
(Figure 3(B)). Both 4-OH-tam and endoxifen were es-
sentially devoid of estrogen agonist activity in this
system (Figure 3(C)).
Gene expression experiments
The effects of endoxifen on the expression of estrogen
responsive genes was compared to that of 4-OH-tam
by northern blot analysis. The inhibition of pS2 ex-
pression by both compounds is shown in Figure 4.
Half maximal inhibition of expression is produced
by both compounds between 3 × 10−8 and 10−7 M,
consistent with the proliferation data.
Discussion
In advanced breast cancer, roughly 35% of patients
with ER positive tumors will not respond to tamox-
ifen therapy, and ultimately all tumors that do respond
will become resistant to the treatment, typically after
a year to 18 months. Thus, much work has been
conducted trying to understand the lack of response
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in tumors that exhibit primary resistance to tamox-
ifen and the mechanisms by which tumors acquire
resistance. One focus of this work has been the pos-
sibility that an altered pattern of metabolism might in
part explain these effects. Tamoxifen is extensively
metabolized, predominantly by the liver, generating
a complex series of compounds that exhibit altered
affinity for ERs and a variety of agonist and an-
tagonist properties [3, 9]. These compounds range
in their activity from strong estrogen antagonists to
potent estrogens. The most abundant metabolite is
N-desmethyl tamoxifen (NDT) which is believed to
be predominantly generated by the cytochrome p450
enzyme (CYP) 3A4. Patients receiving the standard
does of 20 mg of tamoxifen per day typically have
plasma concentrations of NDT of approximately 400–
800 nM, (compared to 250–650 nM tamoxifen) when
they reach steady state, which takes 4–6 weeks since
the half-life of NDT is roughly two weeks [10, 11].
NDT has similar potency to that of tamoxifen and
similar partial agonist activity [9]. Another important
metabolite is 4-OH-tam, which is sometimes referred
to as the active metabolite of tamoxifen, since it is
significantly more potent than the parent compound.
Depending on the assay system used, the apparent
affinity of 4-OH-tam for ER-α is similar to that of
E2, whereas that of tamoxifen is approximately 30–
100-fold less [3]. Plasma concentrations of 4-OH-tam
are however quite low, approximately 1–12 nM, thus
describing 4-OH-tam as the active metabolite is over
simplistic, since it is likely that for most patients
it is the aggregate activity of the parent compound
and metabolites that will determine the response that
is seen. Several of the CYPs are known to be able
to make 4-OH-tam (CYP2D6, CYP2C9, CYP2C19,
CYP3A4) [4, 12].
Tamoxifen is generally a very well tolerated drug,
however one of the most commonly reported side ef-
fects, hot flashes, can be sufficiently severe to lead
to patients stopping their therapy [13]. Since treat-
ment with estrogen is not a logical option for treating
hot flashes in the context of antiestrogen therapy,
several other approaches have been tried and recent
studies have shown that the selective serotonin reup-
take inhibitors (SSRIs) can be useful in this context
[14, 15].
The mechanism by which the SSRI’s can reduce
the incidence of hot flashes is not known, and so a
clinical study was initiated to examine the hypothesis
that the SSRI paroxetine might alter the metabolism
of tamoxifen resulting in the production of less 4-
OH-tam, and thereby reducing the incidence of hot
flashes [4]. This hypothesis was based on the know-
ledge that paroxetine is metabolized by, and can in-
hibit the activity of CYP2D6, one of the enzymes
believed to be responsible for the formation of 4-OH-
tam. No link was found between the incidence of hot
flashes and the levels of any of the tamoxifen meta-
bolites, but the study did show that the level of one
chromatographic peak in the tamoxifen assays of pa-
tient plasma was highly sensitive to co-administration
of paroxetine. This peak was determined to be a
previously described minor tamoxifen metabolite: 4-
hydroxy N-desmethyl tamoxifen [4, 16, 17]. A small
quantity of endoxifen was synthesized to verify the
identity of the chromatographic peak and to evalu-
ate the antiestrogenic activity of the metabolite. We
further showed that endoxifen is almost exclusively
generated by the action of CYP2D6 and that pa-
tients who carry a CYP2D6 genetic polymorphism
that results in reduced enzyme activity, make very
little endoxifen.
The antiestrogenic properties of endoxifen were
not known, and so this study was initiated to charac-
terize the ER binding properties and estrogen agon-
ist/antagonist profile of the compound, as a first step
toward determining the importance of this metabolite
to the overall clinical response of patients undergoing
tamoxifen therapy.
N-desmethyl tamoxifen has very similar proper-
ties to those of tamoxifen and the addition of the
4-hydroxyl group to tamoxifen dramatically increases
the affinity of the compound for the ER. It is, therefore,
not surprising that we find endoxifen to have essen-
tially identical properties to 4-OH-tam with respect
to receptor affinity and effects of cell proliferation
and gene expression. The ER binding characteristics
of endoxifen are indistinguishable from those of 4-
OH-tam as are its estrogen antagonist properties as
determined by the suppression of estrogen stimulated
breast cancer cell proliferation. These findings are en-
tirely consistent with what has recently been learned
about the structural requirements for ER binding and
antiestrogen properties based on the crystal structure
of the ligand binding domain of the ER [18]. Although
we have not conducted an exhaustive comparison of
their actions in all organ systems where estrogen exerts
some effect, based on these data is seems likely that
4-OH-tam and endoxifen are essentially functionally
equivalent.
Data from our previous study [4], from earlier
studies [16, 17], and from a study describing an as-
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say optimized for measuring endoxifen in patients
samples [19], all show that endoxifen concentrations
are notably higher than those of 4-OH-tam. More
extensive ongoing studies have shown that plasma
endoxifen concentrations are typically greater than
those of 4-OH-tam when both drug and metabol-
ite concentrations have reached steady state after 4
months of treatment with endoxifen concentrations
being a mean of 6.8-fold greater (unpublished obser-
vations).
4-OH-tam has frequently been referred to in the
literature as the active metabolite of tamoxifen, how-
ever, based on our present findings, if there is any
validity to the concept of the predominance of a single
active metabolite in response to tamoxifen therapy,
then it is most likely endoxifen and not 4-OH-tam
that is that metabolite. In reality it is more likely
that it is the balance of the concentrations of all of
the metabolites of tamoxifen along with the parent
compound which mediate the clinical effects of the
drug, but the fact remains that endoxifen is likely to
play a significant role in this overall response. This
realization is particularly important in light of our pre-
vious findings that show that plasma concentrations
of endoxifen in patients are notably influenced by
CYP2D6 genotype. There are more than 50 known
genetic polymorphisms of this enzyme and roughly
7% of Caucasian patients do not express functional
enzyme [20, 21]. Thus, it is possible that CYP2D6
genotype may have an important impact on patient
response to tamoxifen since patients with defective
CYP2D6 alleles have much lower plasma concentra-
tions of endoxifen. We have recently described a facile
method for genotyping archival paraffin imbedded tu-
mor blocks for germline polymorphisms in several
clinically important CYPs including CYP2D6 and we
propose to attempt to address the question of the role
of CYP2D6 genotype in tamoxifen response by inter-
rogating historical clinical trials of tamoxifen efficacy
[22]. Certain drugs that are known to inhibit the activ-
ity of CYP2D6 can mimic the effect of inactivating
polymorphisms of the enzyme and reduce plasma con-
centrations of endoxifen [4]. This raises the possibility
that co-administration of these agents might also al-
ter patient response to tamoxifen therapy. Prospective
clinical studies in which patients are genotyped for
all of the relevant phases 1 and 2 metabolic enzymes
and detailed records of concomitant medications are
maintained will, however, be required in order to thor-
oughly evaluate the impact of tamoxifen metabolism
on therapeutic outcome.
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